These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21044307)

  • 21. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.
    May MT; Gompels M; Delpech V; Porter K; Orkin C; Kegg S; Hay P; Johnson M; Palfreeman A; Gilson R; Chadwick D; Martin F; Hill T; Walsh J; Post F; Fisher M; Ainsworth J; Jose S; Leen C; Nelson M; Anderson J; Sabin C;
    AIDS; 2014 May; 28(8):1193-202. PubMed ID: 24556869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment outcome of HAART-treated patients in a resource-limited setting: the Belgrade Cohort Study.
    Jevtović D; Dragovic G; Salemović D; Ranin J; Kušić J; Marinković J; Djurković-Djaković O
    Biomed Pharmacother; 2014 Apr; 68(3):391-5. PubMed ID: 24486106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamics of HIV reservoir decay and naïve CD4 T-cell recovery between immune non-responders and complete responders on long-term antiretroviral treatment.
    Zhang LX; Song JW; Zhang C; Fan X; Huang HH; Xu RN; Liu JY; Zhang JY; Wang LF; Zhou CB; Jin L; Shi M; Wang FS; Jiao YM
    Clin Immunol; 2021 Aug; 229():108773. PubMed ID: 34102315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Routine CD4 monitoring in HIV patients with viral suppression: Is it really necessary? A Portuguese cohort.
    Duro R; Rocha-Pereira N; Figueiredo C; Piñeiro C; Caldas C; Serrão R; Sarmento A
    J Microbiol Immunol Infect; 2018 Oct; 51(5):593-597. PubMed ID: 28712820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy.
    Resino S; Resino R; Leon JA; Bellon JM; Martin-Fontelos P; Ramos JT; Gurbindo-Gutierrez D; de Jose MI; Ciria L; Muñoz-Fernandez MA
    BMC Infect Dis; 2006 Jan; 6():10. PubMed ID: 16433913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
    O'Connor JL; Smith CJ; Lampe FC; Hill T; Gompels M; Hay P; Chadwick D; Fisher M; Ainsworth J; Gilson R; Mackie N; Anderson J; Orkin C; Nelson M; Kegg S; Leen C; Palfreeman A; Post F; Johnson M; Sabin CA; Phillips AN;
    AIDS; 2014 Mar; 28(6):919-24. PubMed ID: 24335482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of early highly active antiretroviral therapy on viral suppression among newly diagnosed men who have sex with men living with human immunodeficiency virus in Xi'an, China.
    Wei X; Zhang Y; Santella AJ; Wang L; Zhuang G; Li S; Zhang H
    J Med Virol; 2019 Jul; 91(7):1263-1271. PubMed ID: 30840771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ethnicity as predictor of immune reconstitution among Malaysian HIV-positive patients treated with highly active antiretroviral therapy.
    Mohamad Isa II; Abu Bakar S; Ab Rahman AK
    J Med Virol; 2020 Aug; 92(8):1173-1181. PubMed ID: 31957025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining CD4 recovery and CD4: CD8 ratio restoration as an indicator for evaluating the outcome of continued antiretroviral therapy: an observational cohort study.
    Lee SS; Wong NS; Wong BCK; Wong KH; Chan KCW
    BMJ Open; 2017 Sep; 7(9):e016886. PubMed ID: 28918411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased early activation of CD56dimCD16dim/- natural killer cells in immunological non-responders correlates with CD4+ T-cell recovery.
    Zhang QY; Zhang X; Su B; Liu LF; Yang XD; Tang B; Xia H; Ma P; Zhang T; Wu H
    Chin Med J (Engl); 2020 Nov; 133(24):2928-2939. PubMed ID: 33252378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid CD4 decline prior to antiretroviral therapy predicts subsequent failure to reconstitute despite HIV viral suppression.
    Darraj M; Shafer LA; Chan S; Kasper K; Keynan Y
    J Infect Public Health; 2018; 11(2):265-269. PubMed ID: 28826735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.